2012-10-09 00:26:20 - New Pharmaceuticals market report from Global Markets Direct: "Vical Incorporated - Product Pipeline Review - 2012"

Global Market Direct's pharmaceuticals report, "Vical Incorporated - Product Pipeline Review - 2012" provides data on the Vical Incorporated's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Vical Incorporated's corporate website, SEC filings, investor presentations and featured press releases, both from Vical Incorporated and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

* Vical Incorporated - Brief Vical Incorporated overview including business description, key information and facts, and its locations and subsidiaries.
* Review of current pipeline of Vical Incorporated human therapeutic division.
*

Overview of pipeline therapeutics across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of Vical Incorporated with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the Vical Incorporated's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.


Full Report Details at
- www.fastmr.com/prod/468619_vical_incorporated_product_pipeline_r ..


Reasons to buy

* Evaluate Vical Incorporated's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of Vical Incorporated in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the Vical Incorporated's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with Vical Incorporated.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of Vical Incorporated and identify potential opportunities in those areas.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Vical Incorporated Snapshot
Vical Incorporated Overview
Key Information
Key Facts
Vical Incorporated - Research and Development Overview
Key Therapeutic Areas
Vical Incorporated - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Vical Incorporated - Pipeline Products Glance
Vical Incorporated - Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Vical Incorporated Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Vical Incorporated - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Vical Incorporated - Drug Profiles
Allovectin + Anti-CTLA-4 Antibody
Product Description
Mechanism of Action
R&D Progress
Allovectin-7
Product Description
Mechanism of Action
R&D Progress
Dacarbazine + Allovectin-7
Product Description
Mechanism of Action
R&D Progress
Dengue Vaccine
Product Description
Mechanism of Action
R&D Progress
H1N1 Vaccine
Product Description
Mechanism of Action
R&D Progress
HIV Vaccine
Product Description
Mechanism of Action
R&D Progress
HSV-2 Vaccine
Product Description
Mechanism of Action
R&D Progress
Vaxfectin TRP-2
Product Description
Mechanism of Action
R&D Progress
VCL-IM01
Product Description
Mechanism of Action
R&D Progress
Vical Incorporated - Pipeline Products by Route of Administration
Vical Incorporated - Pipeline Products By Mechanism of Action
Vical Incorporated - Recent Pipeline Updates
Vical Incorporated - Dormant Projects
Vical Incorporated - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Vaxid
Vical Incorporated - Company Statement
Vical Incorporated - Locations And Subsidiaries
Head Office
Vical Incorporated, Recent Developments
Vical Incorporated- Press Release
May 22, 2012: Vical Publishes Preclinical Results Of Herpes Simplex Vaccine In Journal Of General Virology
May 16, 2012: Vical Presents Update On Herpes Simplex Vaccine Development At ASGCT Conference
Mar 28, 2012: New Malaria DNA Vaccine Candidate Developed Using Vical's Vaxfectin Adjuvant
Mar 05, 2012: U.S. Navy Advances Dengue DNA Vaccine Using Vical's Vaxfectin Adjuvant
Jan 30, 2012: Vical Presents Case Study On Successful Design Of Allovectin Phase III Melanoma Trial At Phacilitate Cell & Gene Therapy Forum 2012
Jan 11, 2012: Vical Provides Update On CyMVectin Prophylactic Vaccine
Dec 29, 2009: Vical Confirms Advantages Of DNA Technology Platform With Vaccine For H1N1 Influenza
Dec 28, 2009: Vical's Allovectin-7 Phase 3 Trial Receives Positive Review From Safety Monitoring Board
Dec 22, 2009: Vical Receives US Patent Coverage For DNA Vaccines Against Herpes Simplex Virus Type-2
Sep 08, 2009: Vical Receives $2.5 Million Payment For Funding of Allovectin-7 Phase 3 Trial
Aug 03, 2009: Vical and Teva Establish Sales And Marketing Agreement For Allovectin-7 In Israel

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468619&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.